ABL Bio Inc.

Equities

A298380

KR7298380007

Biotechnology & Medical Research

End-of-day quote Korea S.E. 06:00:00 2024-07-11 pm EDT 5-day change 1st Jan Change
27,700 KRW +4.33% Intraday chart for ABL Bio Inc. -6.26% +12.60%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial MT
Biocytogen Pharmaceuticals Co., Ltd. Enters Collaboration with ABL Bio Inc. to Develop New Bispecific Antibody-Drug Conjugates CI
ABL Bio Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
I-Mab Doses First Patient in Phase 1 Trial of TJ-CD4B to Treat Solid Tumors MT
ABL Bio Inc. Enters Global Collaboration and License Agreement with SANOFI to Advance ABL301 for the Treatment of Parkinson's Disease CI
I-Mab and ABL Bio Inc. Jointly Announce Preclinical Data of Their 4-1Bb Bispecific Antibodies At the 2021 Society for Immunotherapy of Cancer Annual Meeting CI
Compass Therapeutics, Inc. and ABL Bio Presented Clinical Trial Data for CTX-009 CI
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting CI
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody CI
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific Antibody CI
I-Mab and ABL Bio Inc. Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors CI
I-Mab and ABL Bio Inc. Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors CI
HiFiBiO Therapeutics Announces Global Strategic Partnership with ABL Bio for the Co-Development of SARS-CoV-2 Neutralizing Antibody CI
I-Mab and ABL Bio Inc. to Present Preclinical Data for Joint Bispecific CI
Genscript Biologics Enters into an Agreement with ABL Bio Inc CI
ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index CI
ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index CI
ABL Bio Inc.(KOSDAQ:A298380) added to S&P Global BMI Index CI
ABL Bio Inc. has completed an IPO in the amount of KRW 90 billion. CI
TRIGR Therapeutics, Inc. and ABL Bio, Inc. Enters into Collaboration and License Agreement for TR009 CI
WuXi Biologics and ABL Bio Enter an Exclusive Development and Clinical Manufacturing Partnership for Multiple Bispecific Antibodies CI
ABL Bio Inc. has filed an IPO. CI
Chart ABL Bio Inc.
More charts
ABL Bio Inc. is a company mainly engaged in the development of biopharmaceuticals. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. A298380 Stock
  4. News ABL Bio Inc.
  5. ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial